Fennec Pharmaceuticals
FENC • NASDAQ
Fennec Pharmaceuticals is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Jeffrey S. Hackman, with a market cap of $201.9M.
CEOJeffrey S. Hackman
Next Earnings
Upcoming earnings announcement for Fennec Pharmaceuticals
Date
Tuesday, May 12, 2026 (in a month)
Timing
Before Market Open (6:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.01
Revenue Estimate
$15.4M
Earnings History
Past 12 earnings reports for Fennec Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 24, 2026 | Q4 2025 | -$0.17Est: $0.04 | -525.0% | $13.8MEst: $14.8M | -7.1% |  10-K |
| Nov 13, 2025 | Q3 2025 | -$0.02Est: -$0.05 | +60.0% | $12.5MEst: $11.2M | +11.1% | 10-Q |
| Aug 14, 2025 | Q2 2025 | -$0.11Est: -$0.04 | -175.0% | $9.7MEst: $9.5M | +1.2% | 10-Q |
| May 13, 2025 | Q1 2025 | -$0.04Est: -$0.09 | +55.6% | $8.8MEst: $8.2M | +7.0% | 10-Q |
| Mar 10, 2025 | Q4 2024 | -$0.06Est: -$0.13 | +53.8% | $7.9MEst: $16.4M | -51.7% | 10-K |
| Nov 7, 2024 | Q3 2024 | -$0.21Est: -$0.10 | -110.0% | $7.0MEst: $8.8M | -20.9% | 10-Q |
| Aug 13, 2024 | Q2 2024 | -$0.20Est: -$0.03 | -566.7% | $7.3MEst: $11.1M | -34.3% | 10-Q |
| May 14, 2024 | Q1 2024 | $0.41Est: $0.26 | +57.7% | $25.4MEst: $18.9M | +34.4% | 10-Q |
| Mar 21, 2024 | Q4 2023 | -$0.10Est: -$0.02 | -400.0% | $9.7MEst: $8.7M | +12.3% | 10-K |
| Nov 6, 2023 | Q3 2023 | -$0.07Est: -$0.11 | +36.4% | $6.5MEst: $5.4M | +20.2% | — |
| Aug 3, 2023 | Q2 2023 | -$0.21Est: -$0.16 | -31.2% | $3.3MEst: $3.7M | -10.9% | 10-Q |
| May 11, 2023 | Q1 2023 | -$0.23Est: -$0.21 | -9.5% | $1.7MEst: $1.9M | -9.4% | — |